Research programme: oral mucosal immunotherapy - Intrommune Therapeutics

Drug Profile

Research programme: oral mucosal immunotherapy - Intrommune Therapeutics

Alternative Names: INT-301

Latest Information Update: 07 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intrommune Therapeutics
  • Class Allergens; Allergy immunotherapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Peanut hypersensitivity

Most Recent Events

  • 01 Mar 2016 Intrommune Therapeutics receives patent allowance for Oral Mucosal Immunotherapy platform in USA
  • 01 Jun 2015 Preclinical trials in Peanut hypersensitivity in USA (Transmucosal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top